Current stock page

Financial Data

IDYA Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

IDYAIDEAYA Biosciences, Inc.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$31.83+$0.34 (+1.08%)

Latest quote

  • Momentum
    63
  • Value
    39
  • Quality
    51
  • Risk resilience
    61
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$10.24M$8.86M$6.56M$10.88M$207.83M$0$0$7M
Gross Profit$10.24M$8.86M$6.56M$10.88M$207.83M$0$0$7M
Operating Income-$137.63M-$122.29M-$108.54M-$94.57M$108.45M-$88.81M-$84.39M-$144.14M
Net Income-$125.75M-$112.45M-$98.54M-$83.27M$119.24M-$77.49M-$72.18M-$130.31M
EPS-$1.22-$1.22-$1.11-$0.94$1.35-$0.88-$0.82-$1.49
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$93.48M-$88.21M-$75.17M-$90.5M$142.21M-$62.47M-$60.34M-$121.66M
Capital Expenditure-$273K-$866K-$967K-$333K-$42K-$663K-$1.33M-$1.1M
Free Cash Flow-$93.75M-$89.08M-$76.14M-$90.83M$142.17M-$63.14M-$61.67M-$122.76M
Net Cash Provided By Operating Activities-$93.48M-$88.21M-$75.17M-$90.5M$142.21M-$62.47M-$60.34M-$121.66M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$1.22B$1.31B$1.03B$1.11B$1.19B$1.04B$1.1B$1.12B
Total Debt$29.7M$29.31M$28.6M$55.49M$27.25M$26.6M$25.97M$19.17M
Cash And Cash Equivalents$261.45M$272.59M$157.52M$112.83M$298.93M$114.65M$130M$84.38M
Total Liabilities$123.96M$110.79M$93.08M$86.39M$93.1M$81.62M$76.51M$64.94M
Total Stockholders Equity$1.09B$1.2B$937.27M$1.02B$1.09B$959.65M$1.02B$1.06B
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio2.942.772.732.662.52.221.531.69
P/S ratio89.69———————
Debt To Equity0.030.020.030.050.020.030.030.02
Free Cash Flow Yield-10.88%-5.72%-3.44%-2.70%-3.86%-13.93%-17.09%-14.08%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio2.942.772.732.662.52.221.531.69
P/S ratio89.69———————
Return On Equity-38.46%-14.60%-14.94%-11.11%-14.72%-34.58%-29.98%-25.91%
Debt To Equity0.030.020.030.050.020.030.030.02

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-7.09x
Pb3x
Revenue Growth Yoy-95.07%
EPS Growth Yoy-190.37%
Gross Margin100.00%
Operating Margin-1267.38%
ROE-39.52%
ROIC-41.28%
Debt To Equity0.03
FCF Yield-11.37%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$31.83
Volume778,817
RSI (14)42.42
MACD-1.1
MACD signal-1.2
MACD histogram0.1
ADX (14)25.76
SMA (50)$35.47
SMA (200)$33.85
ATR (14)$1.46
Historical volatility (annualized)48.20%
Volume (20-day average)1.07M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score61/100
Beta0.94
Annual volatility44.94%
Max Drawdown-27.85%
Sharpe Ratio0.14
VaR (95%, 1-day)-4.06%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

IDYA Financial Data FAQ

What is IDEAYA Biosciences, Inc.'s revenue?

IDEAYA Biosciences, Inc.'s revenue is one of the core financial data points for IDYA. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is IDEAYA Biosciences, Inc.'s revenue growing?

Revenue growth shows whether IDEAYA Biosciences, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is IDYA's EPS?

IDYA's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is IDEAYA Biosciences, Inc.'s net income?

IDEAYA Biosciences, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does IDEAYA Biosciences, Inc. generate?

Free cash flow shows how much cash IDEAYA Biosciences, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does IDEAYA Biosciences, Inc. have?

Cash and debt help frame IDYA's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.